Telemetry Investments L.L.C. Has $598,000 Stake in Rigel Pharmaceuticals, Inc. (RIGL)

Telemetry Investments L.L.C. boosted its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by 114.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 260,000 shares of the biotechnology company’s stock after buying an additional 139,000 shares during the quarter. Telemetry Investments L.L.C. owned approximately 0.16% of Rigel Pharmaceuticals worth $598,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Caption Management LLC purchased a new position in Rigel Pharmaceuticals in the fourth quarter valued at $126,000. BlueMountain Capital Management LLC purchased a new position in Rigel Pharmaceuticals in the third quarter valued at $154,000. New Jersey Better Educational Savings Trust increased its holdings in Rigel Pharmaceuticals by 16.7% in the fourth quarter. New Jersey Better Educational Savings Trust now owns 70,000 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 10,000 shares during the last quarter. AQR Capital Management LLC increased its holdings in Rigel Pharmaceuticals by 67.8% in the third quarter. AQR Capital Management LLC now owns 61,779 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 24,961 shares during the last quarter. Finally, Granite Investment Partners LLC purchased a new position in Rigel Pharmaceuticals in the third quarter valued at $231,000. 95.18% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ RIGL traded up $0.06 during midday trading on Friday, reaching $2.36. 9,530 shares of the company were exchanged, compared to its average volume of 2,154,597. Rigel Pharmaceuticals, Inc. has a 1 year low of $1.96 and a 1 year high of $4.68. The firm has a market cap of $384.50 million, a P/E ratio of -5.36 and a beta of 1.25.



Several brokerages have issued reports on RIGL. HC Wainwright set a $8.00 price objective on Rigel Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 4th. Cantor Fitzgerald set a $9.00 price objective on Rigel Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, December 3rd. Finally, Zacks Investment Research raised Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price objective on the stock in a report on Friday, November 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $7.25.

WARNING: This news story was first posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://dakotafinancialnews.com/2019/03/15/telemetry-investments-l-l-c-has-598000-stake-in-rigel-pharmaceuticals-inc-rigl.html.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy.

See Also: Short Selling – Explanation For Shorting Stocks

Want to see what other hedge funds are holding RIGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL).

Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.